The 10-second takeaway
For the quarter ended Dec. 29 (Q1), Hologic missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share dropped significantly.
Margins contracted across the board.
Hologic recorded revenue of $631.4 million. The 19 analysts polled by S&P Capital IQ wanted to see revenue of $645.6 million on the same basis. GAAP reported sales were 34% higher than the prior-year quarter's $472.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.38. The 22 earnings estimates compiled by S&P Capital IQ averaged $0.37 per share. GAAP EPS of $0.01 for Q1 were 88% lower than the prior-year quarter's $0.08 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 56.5%, 600 basis points worse than the prior-year quarter. Operating margin was 8.4%, 900 basis points worse than the prior-year quarter. Net margin was 0.5%, 390 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $649.9 million. On the bottom line, the average EPS estimate is $0.38.
Next year's average estimate for revenue is $2.63 billion. The average EPS estimate is $1.58.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 679 members out of 699 rating the stock outperform, and 20 members rating it underperform. Among 196 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 190 give Hologic a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $23.82.
Is Hologic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Hologic to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.